{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:05:15Z","timestamp":1776413115034,"version":"3.51.2"},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>GLP-1 ist ein Inkretinhormon, das die Insulinsekretion stimuliert, die Glukagonfreisetzung hemmt und weitere metabolische Prozesse beeinflusst. GLP-1-Rezeptoragonisten (GLP-1-RA) r\u00fccken zunehmend in den Fokus der Nephrologie, insbesondere im Kontext der chronischen Nierenerkrankung (CKD) bei Patienten mit Typ-2-Diabetes mellitus (T2DM). Urspr\u00fcnglich als Antidiabetika entwickelt, zeigen sie neben ihrer blutzuckersenkenden Wirkung auch kardiovaskul\u00e4re und nephroprotektive Effekte.<\/jats:p><jats:p>Bei T2DM-Patienten ist die Funktion dieses Systems beeintr\u00e4chtigt, was zur Entwicklung spezifischer, langwirksamer GLP-1-RA gef\u00fchrt hat. Sie f\u00fchren zu einer HbA1c-Reduktion von bis zu 1,9% und weisen im Vergleich zu Insulin ein geringeres Hypoglyk\u00e4mierisiko auf. Auch in der Adipositastherapie spielen sie eine zunehmend zentrale Rolle. \u00dcber zentrale Mechanismen im Hypothalamus sowie periphere Effekte, wie die Verz\u00f6gerung der Magenentleerung, senken sie das K\u00f6rpergewicht. Dar\u00fcber hinaus belegen gro\u00dfe kardiovaskul\u00e4re Endpunktstudien, dass GLP-1-RA das Risiko f\u00fcr kardiovaskul\u00e4re Ereignisse signifikant reduzieren.<\/jats:p><jats:p>Erste Hinweise auf nephroprotektive Effekte von GLP-1-RA stammen aus diesen kardiovaskul\u00e4ren Endpunktstudien. Die FLOW-Studie untersuchte erstmals gezielt die nephroprotektiven Effekte von Semaglutid bei Patienten mit CKD und T2DM und konnte beeindruckende, nephroprotektive Ergebnisse aufzeigen. Die aktuelle Studienlage best\u00e4tigt auch die nephroprotektiven Effekte von GLP-1-RA bei CKD-Patienten mit T2DM, und weitere Evidenz f\u00fcr ihren Einsatz wird erwartet. Besonders bedeutsam wird die Frage sein, ob auch CKD-Patienten ohne begleitenden T2DM von einer GLP-1-RA-Therapie profitieren oder ob die Kombination mit SGLT2-Inhibitoren additive nephroprotektive Effekte bietet. Die Entwicklung von GLP-1-RA ist ein bedeutender Fortschritt, erfordert jedoch eine enge interdisziplin\u00e4re Zusammenarbeit und optimierte Versorgungsstrukturen, um Hochrisikopatienten bestm\u00f6glich zu behandeln.<\/jats:p>","DOI":"10.1055\/a-2420-6176","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T23:08:26Z","timestamp":1747696106000},"page":"696-702","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1-RA \u2013 \u201eNew kid on the block\u201c in der Nephrologie?"],"prefix":"10.1055","volume":"150","author":[{"given":"Leonie","family":"Kraft","sequence":"additional","affiliation":[{"name":"Allg. Innere Medizin u. Nephrologie, Robert-Bosch-Krankenhaus, Stuttgart, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"Schanz","sequence":"additional","affiliation":[{"name":"Allg. Innere Medizin u. Nephrologie, Robert-Bosch-Krankenhaus, Stuttgart, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Latus","sequence":"additional","affiliation":[{"name":"Allg. Innere Medizin u. Nephrologie, Robert-Bosch-Krankenhaus, Stuttgart, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s13300-019-0669-4","article-title":"Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force","volume":"10","author":"S Kalra","year":"2019","journal-title":"Diabetes Ther"},{"issue":"06","key":"ref2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"MA Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"09","key":"ref3","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects","volume":"44","author":"CF Deacon","year":"1995","journal-title":"Diabetes"},{"issue":"26","key":"ref4","doi-asserted-by":"crossref","first-page":"19650","DOI":"10.1016\/S0021-9258(19)36565-2","article-title":"Exendin-4 is a high potency agonist and truncated exendin-(9\u201339)-amide an antagonist at the glucagon-like peptide 1-(7\u201336)-amide receptor of insulin-secreting beta-cells","volume":"268","author":"R G\u00f6ke","year":"1993","journal-title":"J Biol Chem"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"M Nauck","year":"2009","journal-title":"Diabetes Care"},{"issue":"15","key":"ref6","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial","volume":"318","author":"M Davies","year":"2017","journal-title":"Jama"},{"issue":"01","key":"ref7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"MA Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"J Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"SJ Nicholls","year":"2024","journal-title":"Am Heart J"},{"issue":"11","key":"ref10","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"HJL Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"MA Nauck","year":"2021","journal-title":"Mol Metab"},{"issue":"02","key":"ref12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/dom.12842","article-title":"A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients","volume":"19","author":"MS Abd El Aziz","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"20","key":"ref13","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4239\/wjd.v7.i20.572","article-title":"Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity","volume":"7","author":"A Anandhakrishnan","year":"2016","journal-title":"World J Diabetes"},{"issue":"02","key":"ref14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial","volume":"327","author":"DM Rubino","year":"2022","journal-title":"Jama"},{"issue":"24","key":"ref15","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"AM Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"04","key":"ref16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"SP Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"AF Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"19","key":"ref18","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"SP Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"N Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"HC Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"SL Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"V Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"03","key":"ref23","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s12020-024-03757-9","article-title":"Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future","volume":"84","author":"I Caruso","year":"2024","journal-title":"Endocrine"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3390\/biomedicines10071661","article-title":"Nephroprotective Effects of Semaglutide as Mono- and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease","volume":"10","author":"LS Dalb\u00f8ge","year":"2022","journal-title":"Biomedicines"},{"issue":"04","key":"ref25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/MNH.0000000000000894","article-title":"Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease","volume":"32","author":"RZ Alicic","year":"2023","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"S 03","key":"ref26","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfac070.013","article-title":"MO399: Remodel: A Mechanistic Trial Evaluating the Effects of Semaglutide on the Kidneys In People With Type 2 Diabetes and Chronic Kidney Disease","volume":"37","author":"P Bjornstad","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"07","key":"ref27","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"HM Colhoun","year":"2024","journal-title":"Nat Med"},{"issue":"01","key":"ref28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","volume":"31","author":"EM Apperloo","year":"2025","journal-title":"Nat Med"},{"issue":"08","key":"ref29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","author":"EM Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"JFE Mann","year":"2024","journal-title":"Nat Med"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2420-6176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T23:08:37Z","timestamp":1747696117000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2420-6176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,5,19]]},"published-print":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2420-6176","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]}}}